AI Insight
An experimental oral medication for advanced pancreatic cancer has demonstrated significantly improved survival outcomes compared to standard chemotherapy treatment. Patients taking the daily pill lived approximately twice as long as those receiving conventional intravenous chemotherapy. The drug represents a potential major advancement in treating this particularly aggressive form of cancer.
Why it matters
Pancreatic cancer has one of the lowest survival rates among cancers, and treatment options have been extremely limited. If approved, this oral medication could provide a more convenient and significantly more effective treatment option for patients with advanced disease, potentially extending life expectancy substantially.
Understand the Science
People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving chemotherapy infusions
Source: 'Transformative' pancreatic cancer drug doubles survival time